Zeltia Group Reports Positive EBITDA in First Half of 2010

- Group sales increased by 31% with respect to the same period in 2009

- Sales increased by 60% in the Biopharmaceutical division and by 10% in the Consumer chemicals division with respect to the previous year

MADRID, July 29 /PRNewswire/ -- Group revenues amounted to 78.7 million euro (approximately 102.9 million USD*) through June 2010, i.e. an increase of 30.8% with respect to the same period last year (60.2 million euro; approximately 78.7 million USD).

Net sales in the Biopharmaceutical business amounted to 37.6 million euro or approximately 49.2 million USD (22.7 million euro in 1H09; approximately 29.7 million USD), of which 33.6 million euro (approximately 43.9 million USD) correspond to Yondelis sales (19.4 million euro in 1H09; approximately 25.4 million USD). Genomica reported revenues of 3.9 million euro (approximately 5.1 million USD), an increase of 19% with respect to June 2009.

Net sales by the consumer chemicals subsidiaries totaled 40.7 million euro or approximately 53.2 million USD (37.1 million euro in 2009; approximately 48.5 million USD). Those companies accounted for 51.6% of the Group's total revenues in the first half of 2010 (61.6% in the first half of 2009).

In the first half of 2010, the Group attained positive EBITDA amounting to 1.6 million euro (approximately 2.1 million USD), primarily attributable to the substantial increase in sales and to Group-wide optimization of operating costs.

The net cash position at June 30, 2010 was 18.2 million euro (approximately 23.8 million USD).

Net income attributable to the parent company improved 54% with respect to 1H09.

About Zeltia:

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine- derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative central nervous system diseases; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3077.

SOURCE Zeltia